Zydus Lifesciences arm to acquire U.S. oncology firm Assertio for $166 million
The transaction is structured as a tender offer to be followed by a merger, subject to customary closing conditions, including the tender of shares representing at least a majority of the total number of outstanding shares of Assertio common stock. | Photo Credit: Getty Images/istockphoto Zydus Lifesciences Ltd has announced that Zydus Worldwide DMCC, it’s subsidiary…
Read More “Zydus Lifesciences arm to acquire U.S. oncology firm Assertio for $166 million” »